Current Headlines

1. Orion Pharma's ODM-212 Granted Orphan Drug Designation In Mesothelioma By The US FDA 4/23/2026

   Orion Corporation (Orion Pharma) today announced that its investigational drug ODM-212 has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for the treatment of mesothelioma, which is a rare and difficult to treat cancer.

2. ImmunoForge To Accelerate CNS Drug Development With Innovative BBB Shuttle Platform 'LMT15' 4/22/2026

   ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company specializing in treatments for rare and muscular diseases, is poised to redefine Central Nervous System (CNS) drug delivery with its proprietary LMT15 Platform, a next-generation Blood-Brain Barrier (BBB) shuttle technology.

3. Celerion Announces Majority Investment From THL Partners 4/22/2026

   Celerion, a global leader in clinical pharmacology and bioanalytical sciences, today announced a majority investment from THL Partners (“THL”), a premier private equity firm investing in middle market growth companies.

4. IOI Launches New Antifungal Drug Discovery Programme 4/21/2026

   The Ineos Oxford Institute for antimicrobial research (IOI) has established a new antifungal drug discovery programme to address the growing global threat of fungal infections and antifungal resistance.

5. Insilico Medicine Announces Industry's First Longevity Board To Accelerate AI-Driven Aging Research For Drug Discovery 4/21/2026

   Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the strategic formation of the industry's first Longevity Board (Board).

6. Belite Bio Initiates Rolling Submission Of New Drug Application To The U.S. Food And Drug Administration For Tinlarebant For The Treatment Of Stargardt Disease 4/21/2026

   Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has initiated a rolling submission of an New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant, an investigational novel oral therapy for the treatment of Stargardt disease type 1 (STGD1), a rare, inherited retinal disorder caused by mutations in the ABCA4 gene.

7. Leinco Technologies And CellCarta Collaborate To Advance Proteomics Solutions And Applications For Drug Development 4/20/2026

   Leinco Technologies, a leader in antibody and protein development, and CellCarta, a global provider of precision medicine laboratory services, are pleased to announce a strategic collaboration aimed at advancing proteomics solutions that will benefit the development of immuno-oncology and other targeted therapeutic modalities.

8. NUS Scientists Devise AI Model That 'Reads' Protein Pairs, Unlocking New Insights Into Disease And Drug Discovery 4/20/2026

   Researchers led by Professor Zhang Yang, Senior Principal Investigator from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore, have developed a new artificial intelligence (AI) model that can more accurately predict how proteins interact with one another—an advance that could accelerate drug discovery and deepen insights into diseases such as cancer.

9. Global First | NMPA Accepts IND Application For Mabwell's Innovative LILRB4/CD3 TCE Bispecific Antibody 6MW5311 4/16/2026

   Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application for its innovative LILRB4/CD3 TCE bispecific antibody (R&D code: 6MW5311).

10. New Cardio-Oncology Drug Aims To Protect The Heart While Increasing Effectiveness Of Cancer Treatments 4/15/2026

    A team of University of Alberta researchers has developed a cardio-oncology drug that protects the heart from chemotherapy damage while enhancing the effectiveness of cancer treatments against tumour growth and spread.